FY20 Annual Report
The 2020 financial year was challenging and one for which we evolved rapidly to meet head on. Managing the impact of COVID-19 is one of the fundamental challenges that all companies have faced this year. In light of COVID-19 and the evolving advice to the general public, Dimerix implemented a number of contingency plans in the event trial participants were required to self-isolate, became ill or visits to medical institutions were restricted. Thanks to the foresight of the operational team running the DMX-200 studies who started implementation of these risk-mitigation strategies in February 2020, we were delighted to meet all of our key milestones on schedule.
Download Opens in new window